PARAGARD has high patient satisfaction

*Data are from the Contraceptive CHOICE Project. The study evaluated 3- and 6-month self-reported bleeding and cramping patterns in 5011 Long-Acting Reversible Contraceptive (LARC) users (n=826, PARAGARD), and the association of these symptoms with method satisfaction. Study participants rated satisfaction with their LARC method as "very satisfied," "somewhat satisfied," or "not satisfied." For the data analyses, "satisfied" and "very satisfied" were grouped together as "satisfied."1

Bleeding Profile

PARAGARD users may experience heavier, longer periods and spotting between periods after placement, but this generally subsides after 2-3 months2

PARAGARD is hormone free, so patients should keep their menstrual cycle3
  • Some women may wish to keep a menstrual cycle for a variety of personal or cultural reasons4

Patients should be advised to call their healthcare professional if spotting persists or their menstrual flow continues to be heavy or long if a woman misses her period, she must promptly be evaluated for pregnancy2

Continuation Rates

Contraceptive continuation rates at 12 months among women ≥26 years of age (n=2956)5†‡

LNG-20-US=Ievonorgestrel 20 mcg/day intrauterine system.
From the Contraceptive CHOICE Project (n=7472). A prospective cohort study to determine the continuation rates and satisfaction levels with many reversible methods of contraception. To be included in this analysis, study participants had to initiate their chosen contraceptive within 3 months of CHOICE enrollment and reach the time point for a 12-month follow-up telephone survey. Follow-up telephone interviews were conducted at 3, 6, and 12 months. A "continuer" was a participant who reported using her baseline contraceptive without stopping temporarily for ≥1 month.5
Chart does not compare the safety or efficacy of these methods.

INDICATION

PARAGARD is indicated for intrauterine contraception for up to 10 years.

IMPORTANT SAFETY INFORMATION

  • PARAGARD does not protect against HIV/AIDS or other sexually transmitted infections (STI).
  • PARAGARD must not be used by women who are pregnant or may be pregnant as this can be life threatening and may result in loss of pregnancy or fertility.
  • PARAGARD must not be used by women who have acute pelvic inflammatory disease (PID) or current behavior suggesting a high risk of PID; have had a postpregnancy or postabortion uterine infection in the past 3 months; have cancer of the uterus or cervix; have an infection of the cervix; have an allergy to any component; or have Wilson’s disease.
  • The most common side effects of PARAGARD are heavier and longer periods and spotting between periods; for most women, these typically subside after 2 to 3 months.
  • If a woman misses her period, she must be promptly evaluated for pregnancy.
  • Some possible serious complications that have been associated with intrauterine contraceptives, including PARAGARD, are PID, embedment, perforation of the uterus, and expulsion.

Click here for the full Prescribing Information for PARAGARD.

Reference: 1. Diedrich JT, Desai S, Zhao Q, et al. Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction. Am J Obstet Gynecol. 2015;212(1): 50.e1-50.e8. 2. PARAGARD® T380A [Prescribing Information]. North Wales, PA: Teva Women's Health, Inc.; September 2014. 3. Kaneshiro B, Aeby T. Long-term safety, efficacy, and patient acceptability of the intrauterine Copper T-380A contraceptive device. lnt J Womens Health. 2010;2:211-220. 4. Data on file. Market research, June 2015. Teva Women's Health, Inc. 5. Rosenstock JR, Peipert JF, Madden T, et al. Continuation of reversible contraception in teenagers and young women. Obstet Gynecol. 2012;120(6):1298-1305.

IMPORTANT SAFETY INFORMATION

  • PARAGARD does not protect against HIV/AIDS or other sexually transmitted infections (STI).
  • PARAGARD must not be used by women who are pregnant or may be pregnant as this can be life threatening and may result in loss of pregnancy or fertility.
continue reading